HPC2/ELAC2 polymorphisms and prostate cancer risk: analysis by age of onset of disease.
The candidate prostate cancer susceptibility gene HPC2/ELAC2 has two common coding polymorphisms: (Ser-->Leu 217) and (Ala-->Thr 541). The Thr541 variant in the HPC2/ELAC2 gene has previously been reported to be at an increased frequency in prostate cancer cases. To evaluate this hypothesis we genotyped 432 prostate cancer patients (including 262 patients diagnosed <or=55 years) and 469 UK, population based control individuals with no family history of cancer. We found no significant difference in the frequencies of Thr541-containing genotypes between cases and controls (OR=1.41, 95% CI 0.79-2.50). The association remained non-significant when the analysis was restricted to cases divided by age of onset into those diagnosed <or=55 years (OR=1.50, 95% CI 0.79-2.85) or to patients diagnosed >55 years (OR=1.27, 95% CI 0.59-2.74). We conclude that any association between the Thr541 variant and prostate cancer is likely to be weak.
Meitz
J C
JC
Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK.
Edwards
S M
SM
Easton
D F
DF
Murkin
A
A
Ardern-Jones
A
A
Jackson
R A
RA
Williams
S
S
Dearnaley
D P
DP
Stratton
M R
MR
Houlston
R S
RS
Eeles
R A
RA
D000328:Adult; D017668:Age of Onset; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D004247:DNA / Q000097:blood / Q000235:genetics; D004273:DNA, Neoplasm / Q000378:metabolism; D005260:Female; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D014644:Genetic Variation / Q000235:genetics; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D009363:Neoplasm Proteins / Q000235:genetics*; D016017:Odds Ratio; D011110:Polymorphism, Genetic; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000473:pathology; D012307:Risk Factors
D004273:DNA, Neoplasm; C421605:ELAC2 protein, human; D009363:Neoplasm Proteins; D004247:DNA